SZL-P1-41

SZL-P1-41 is a small molecule research compound that functions as a selective inhibitor of S-phase kinase-associated protein 2 (Skp2). It acts by binding to the F-box domain of Skp2, which prevents its association with Skp1 and inhibits the formation of the Skp2 SCF (Skp1-Cullin-F-box) E3 ligase complex. This inhibition prevents the ubiquitination and subsequent degradation of Skp2 substrates, most notably the cyclin-dependent kinase inhibitor p27 and the kinase Akt. By stabilizing p27, SZL-P1-41 promotes apoptosis and cellular senescence in cancer cells. Furthermore, by inhibiting Akt ubiquitination, it impairs Akt-driven glycolysis. Preclinical studies have demonstrated its anti-tumor activity in various cancer models, including pancreatic ductal adenocarcinoma, and its potential therapeutic utility in treating pulmonary fibrosis.

Other names

3-(2-Benzothiazolyl)-6-ethyl-7-hydroxy-8-(1-piperidinylmethyl)-4H-1-benzopyran-4-one